WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007004510) PHARMACEUTICAL FOR USE IN THE TREATMENT OF CEREBRAL INFARCTION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/004510    International Application No.:    PCT/JP2006/312996
Publication Date: 11.01.2007 International Filing Date: 29.06.2006
IPC:
A61K 31/5375 (2006.01), A61K 38/48 (2006.01), A61K 45/00 (2006.01), A61P 9/10 (2006.01), A61P 25/00 (2006.01), C07D 295/12 (2006.01)
Applicants: TAISHO PHARMACEUTICAL CO., LTD. [JP/JP]; 24-1, Takada 3-chome, Toshima-ku, Tokyo 1708633 (JP) (For All Designated States Except US).
OMURA, Tomohiro [JP/JP]; (JP) (For US Only).
MIYATA, Noriyuki [JP/JP]; (JP) (For US Only).
OKUYAMA, Shigeru [JP/JP]; (JP) (For US Only)
Inventors: OMURA, Tomohiro; (JP).
MIYATA, Noriyuki; (JP).
OKUYAMA, Shigeru; (JP)
Agent: ASAMURA, Kiyoshi; Room 331, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo 1000004 (JP)
Priority Data:
2005-190985 30.06.2005 JP
Title (EN) PHARMACEUTICAL FOR USE IN THE TREATMENT OF CEREBRAL INFARCTION
(FR) MÉDICAMENT POUR LE TRAITEMENT D'UN INFARCTUS CÉRÉBRAL
(JA) 脳梗塞治療用の医薬
Abstract: front page image
(EN)Disclosed is a pharmaceutical which has an excellent therapeutic effect on cerebral infarction and an excellent ameliorating effect on a dysfunction or neurologic deficit induced by cerebral infarction and produces little adverse side effects. A pharmaceutical comprising a combination of N-(3-chloro-4-morpholin-4-yl)phenyl-N’- hydroxyimidoformamide with a thrombolytic agent such as urokinase, alteplase, desmoteplase, tisokinase, nasaruplase, nateplase, pamiteplase, monteplase or batroxobin.
(FR)La présente invention décrit un médicament dont l'effet thérapeutique sur l'infarctus cérébral est excellent et dont l'effet soulageant sur un dysfonctionnement ou un déficit neurologique induit par un infarctus cérébral est également excellent, ledit médicament ne présentant que des effets secondaires restreints. La présente invention décrit notamment un médicament comprenant une combinaison de N-(3-chloro-4-morpholin-4-yl)phényl-N’-hydroxyimidoformamide et d'un agent thrombolytique tel que l’urokinase, l’altéplase, la desmotéplase, la tisokinase, la nasaruplase, la natéplase, la pamitéplase, la montéplase ou la batroxobine.
(JA) 脳梗塞治療、又は脳梗塞に起因する機能不全もしくは神経脱落症状の改善に優れ、且つ、副作用の少ない医薬を提供する。  N-(3-クロロ-4-モルホリン-4-イル)フェニル-N’-ヒドロキシイミドホルムアミドと、ウロキナーゼ、アルテプラーゼ、デスモテプラーゼ、チソキナーゼ、ナサルプラーゼ、ナテプラーゼ、パミナプラーゼ、モンテプラーゼまたはパトロキソビンなどの血栓溶解薬とを組み合わせてなる医薬とする。
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)